‘One-two-punch' cancer vaccine weaponises the immune system to attack ANY tumour – raising hopes of universal jab
TAKEDOWN 'One-two-punch' cancer vaccine weaponises the immune system to attack ANY tumour – raising hopes of universal jab
A NEW experimental cancer jab could one day be used to fight any type of tumour, US scientists claim.
Experts from the University of Florida say they've developed a powerful mRNA vaccine that trains the immune system to target and destroy cancer cells.
1
The discovery brings us closer to a universal cancer jab that could work across many tumour types
Credit: Getty
It's dubbed the 'one-two punch' after the powerful boxing move where a jab sets up a cross to knock the opponent down.
This is because this jab also works in two steps: first by waking up the immune system, then helping it attack cancer cells more effectively.
It does this by boosting the effects of immunotherapy, a type of cancer treatment that helps the immune system recognise and attack cancer cells.
The groundbreaking discovery brings us closer to a universal cancer jab that could work across many tumour types, it is hope
Research in mice showed that combining the jab with a common immunotherapy drug called an immune checkpoint inhibitor helped fight even resistant tumours.
Dr Elias Sayour, the study's senior author, said: 'This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumour or virus, so long as it is an mRNA vaccine, could lead to tumour-specific effects.'
He added: 'This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccines to sensitise the immune system against a patient's individual tumour.'
Unlike previous cancer vaccines that try to hone in on a particular protein in the cell, the new jab works by simply firing up the immune system, tricking it into responding as if it were under viral attack.
By boosting levels of a protein called PD-L1 inside tumours, it makes them more receptive to immunotherapy and helps immune cells recognise them as dangerous.
Lead scientist Dr Duane Mitchell, co-author of the study, said: 'What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction.
The signs and symptoms of cancer
'And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine.'
For the past eight years, Dr Sayour's lab has been developing cutting-edge vaccines using the same mRNA technology found in Covid jabs.
Last year, they trialled a personalised version in four patients with glioblastoma - an aggressive and usually deadly brain tumour.
They saw a fast and fierce immune response that helped fight off the cancer.
'Profound'
The latest study, published today in Nature Biomedical Engineering, tested a more generalised version of the jab, not tailored to individual tumours, and still saw dramatic results.
In mice with melanoma, a type of deadly skin cancer, combining the jab with an immunotherapy drug called a PD-1 inhibitor led to tumour shrinkage
While in some skin, bone, and brain cancer models, the jab alone eliminated tumours completely.
Dr Sayour explained: 'Even an immune response that is seemingly unrelated to the cancer may be able to activate T cells that weren't working before, allowing them to multiply and kill the tumour if the response is strong enough.'
Dr Mitchell said: 'It could potentially be a universal way of waking up a patient's own immune response to cancer.
'And that would be profound if generalisable to human studies.'
The team are now working to improve the formula and begin human trials as soon as possible.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
3 hours ago
- Daily Mail
How Covid led to an 'acceleration' in brain ageing (even if you didn't have the virus)
The Covid pandemic 'significantly' accelerated brain ageing – even among those who were never infected, a study suggests. Scientists say the strain on people's lives, from isolation for weeks on end to the uncertainty surrounding the crisis, was 'detrimental' to the nation's health. The findings emerged from a brain ageing model created using data from 15,334 healthy people. This model was then used to analyse brain scans from another 996 healthy people. Half had scans taken before the pandemic and half had scans before and after the pandemic. The latter group's brains were found to have aged an average of 5.5 months faster. Some had even aged an extra 20 months faster. This accelerated ageing during the pandemic was seen regardless of whether the participants had been infected. However, Covid infection was linked to an increased rate of acceleration as participant age increased. Brain ageing was also more pronounced in men and for those experiencing socioeconomic disadvantage such as a lack of employment, low levels of income, poor health and lower levels of education. The researchers also used tests taken by participants to assess cognitive performance. For those infected with Covid, these showed a decline in performance – particularly in mental flexibility and processing speed. The scientists, from Nottingham University, said: 'We found that the pandemic was detrimental to brain health and induced accelerated brain ageing regardless of infection.' Dr Ali-Reza Mohammadi-Nejad, who led the study, told journal Nature Communications: 'What surprised me most was that even people who hadn't had Covid showed significant increases in brain ageing rates. 'It really shows how much the experience of the pandemic, everything from isolation to uncertainty, may have affected our brain health.' His colleague Professor Dorothee Auer added: 'The pandemic put a strain on people's lives, especially those already facing disadvantage.'
Scottish Sun
4 hours ago
- Scottish Sun
Ozempic-like fat jabs are BETTER than common drug at reducing dementia risk, study finds
Plus, all the ways you can lower your dementia risk if you have type 2 diabetes WIN WIN Ozempic-like fat jabs are BETTER than common drug at reducing dementia risk, study finds Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, say scientists. While both medications demonstrate neuroprotective properties, no comparison has been made up until now. Sign up for Scottish Sun newsletter Sign up 1 GLP-1 receptor agonists have recently gained popularity as a weight loss medication Credit: Getty Metformin is generally the first-line medication for type 2 diabetes, while GLP-1 receptor agonists are often used as second-line or add-on therapy when metformin is not sufficient or tolerated. In recent times, GLP-1 receptor agonists have gained popularity as a weight loss medication due to their ability to suppress appetite and promote feelings of fullness. Previously published research indicated people with type 2 diabetes have a significantly increased risk of developing dementia, with some studies reporting a 70 per cent higher risk compared to those without diabetes. And both GLP-1 receptor agonists and metformin have been shown to protect the brains of people with type 2 diabetes. But in the largest study of its kind, published in BMJ Open Diabetes Research & Care, GLP-1 receptor agonists were found to trump metformin when it comes to dementia risk. Researchers analysed health records from the period 2004 to 2024 to track the development of dementia in patients with type 2 diabetes who were treated with either GLP-1 receptor agonists or metformin for at least six consecutive months. While there was no significant difference in vascular dementia risk between the two types of drug, GLP-1 receptor agonist use was associated with a significantly lower risk of developing dementia, overall. Specifically, taking GLP-1 receptor agonists was linked to a lower risk of developing Alzheimer's disease, and a 25 per cent lower risk of developing non-vascular dementias than metformin use. These positive effects were evident across all age groups, but with the strongest effect among the over 60s, women, and those of white ethnicity. Risk of death from any cause was also found to be lower - nearly 5 per cent of those treated with GLP-1 receptor agonists died compared with nearly 9 per cent of those treated with metformin. The 14 science-backed ways to prevent dementia 'Both medications demonstrate neuroprotective properties, such as reducing neuroinflammation and oxidative stress, improving insulin sensitivity, and enhancing cerebrovascular health, which likely contribute to their benefits in overall dementia,' explain the researchers. But unlike metformin, GLP-1 receptor agonists exert direct central nervous system effects by crossing the blood-brain barrier, they add. The researchers point out their tracking period, while sufficient for observing dementia outcomes, may not fully capture long-term cognitive effects, especially given the progressive nature of Alzheimer's disease. But they conclude: "Given the severe societal, familial , and economic burden of diabetes-related dementia, these findings raise important considerations about the tole of GLP-1 [receptor agonists] as first-line therapies in [type 2 diabetes] management. "While further long-term studies are warranted to validate these results, integrating GLP-1 [receptor agonists] as primary therapeutic agents may represent a paradigm shift in preventing the cognitive complications of diabetes.' All GLP-1 medicines are prescription only medicines, which means they can only be prescribed by a healthcare professional. GLP-1 medicines can also be purchased privately. If you want to get a GLP-1 medicine privately, a consultation with a healthcare professional must happen before the prescription can be issued, so the prescriber can carry out proper checks and make sure you are aware of the benefits and risks of taking the medicine. GLP-1 medicines should not be bought from unregulated sellers such as beauty salons or via social media, or from anywhere without a prior consultation with a healthcare professional. The Medicines & Healthcare products Regulatory Agency (MHRA) has had reports of people experiencing severe side effects from fake GLP-1 medicines.
Scottish Sun
6 hours ago
- Scottish Sun
Three-year trips to Mars in 2030s, spaceship holidays & budget rocket trips to race around Earth, UK space hero predicts
The astronaut even gazes 100 years into the future PEAKE AT THE FUTURE Three-year trips to Mars in 2030s, spaceship holidays & budget rocket trips to race around Earth, UK space hero predicts SPACE isn't just for scientists and celebs – it'll be a hot holiday destination and will offer a shortcut to slash flight times too. They're just some of the predictions from British space hero Tim Peake, who sat down with The Sun for a chat about our off-Earth future. 9 Space hero Tim Peake was Britain's first European Space Agency astronaut Credit: Getty 9 Peake, who hails from Sussex, spent half a year on board the ISS Credit: Publicity - Getty Tim, 53, spent about 186 days in space, returning from the ISS on June 18, 2016. But when humans start making the first trips to Mars in the next decade or so, they'll be in space for a lot longer – potentially for three years. It sounds nightmarish, but Tim says we've done it all before, hundreds of years ago. 'A lot of people today forget about what we used to do in terms of exploration, the hardships, the torture, the kind of risk that was taken,' Tim told The Sun at Goodwood Festival of Speed's Future Lab earlier this month. 'And in the early 1800s, nothing was thought about disappearing off on a three year expedition. 'That was pretty standard if you were in the Royal Navy. You say goodbye to your family and your mum. 'You say goodbye. You don't really know where you're going or what you're going to be doing, but you're just going to be away for a long time. 'So when I talk to people about in the mid 2030s, we're going to be on a three year mission to Mars and they kind of have this shock and horror that, well, that's so long, you'll never get people to go away for that long. 'Well, you will. We've done this before. 'It's only in the last 150 years that it hasn't been normal to have a three year expedition away, finding new lands and discovering new things. Nasa reveals mesmerising footage of Northern Lights from ISS 'And we're going to kind of go back into that kind of mindset. It's just that it won't be on Earth. It will be out into space.' Nasa hopes to make manned trips to Mars as soon as the 2030s, although no firm date has been set. But whenever those first visits happen, the astronauts will likely be a lot more comfortable than explorers of the past. 'The levels of resilience and self-sufficiency they needed was unbelievable. I mean, again, when we do Mars, the crew will have enough food, they'll have enough water, they'll have enough life support,' Tim said. 9 Six-month trips to the ISS will be nothing compared to a three-year Mars trek Credit: Getty He continued: 'We've mapped the surface, we'll have habitation modules for them. 'So it'll probably be a lot more comfortable than it would be setting off on endurance or HMS Wager back in the day.' SPACE STAYS For now, going to space is largely the preserve of professional astronauts, celebs and the ultra-wealthy. But in the future, Tim thinks that this will soon change – and Elon Musk is partly to thank. Tim credits Musk's company SpaceX with making space travel a lot cheaper. 'They've brought the cost of getting to space down so much, which is really exciting. 'Because that opens up whole markets of things you didn't think were possible because they were cost-prohibitive five or 10 years ago, that are now economically viable. 'So that's really exciting, but SpaceX is just the Uber that gets you there and back. 9 A return trip to and from Mars will be long and arduous – but Tim says explorers will be more than capable of surviving the time away from home Credit: Getty 'What's even more exciting is: now what can you do when you're up there?' Tim tells me that space tourism has been around for a long time – but it's becoming more frequent. And that's a trend that will only grow with time. 'It's part of the democratisation of space,' Tim told The Sun. 'I think fast-forward 100 years and there'll be an awful lot of people going to space for a variety of different reasons. 'Some for science, some for exploration, some for entertainment, and some for a different holiday.' Unsurprisingly, Tim reckons that we'd all be better off if we'd taken a trip to space. He says it gives you a different view of the world – and not just literally. WHO IS TIM PEAKE? Here's what you need to know... Major Tim Peake is a British Army officer and astronaut He is the first British astronaut with the European Space Agency He's also the sixth Brit to go aboard the International Space Agency Peake was born in Chichester, West Sussex in 1972 In 1990 he attended the Royal Military Academy Sandhurst In 1992, he joined the Army Air Corps Then two years later Peake became a qualified helicopter pilot Peake left the army in 2009 to follow his dream of becoming an astronaut He beat more than 9,000 applicants for one of six spots on the ESA's astronaut training programme He had to endure a rigorous selection process that tested his intellect and fitness Peake was launched to the ISS on December 15, 2015 In April the next year, he ran the 2016 London Marathon from the ISS treadmill And in June 2016, he finally returned to Earth, landing in Kazakhstan on a Soyuz descent module During his time in space, Peake completed roughly 3,000 orbits of Earth Picture Credit: Getty Images 'I think it is amazing. The more people that can witness Earth from space – Earth would be a better place. Definitely,' Tim said. 'People would have perhaps have a different perspective when they're making decisions. 'Having kind of seen how we all share one planet. And it looks fairly remote and isolated from space.' So your Moon vacation in 2065 won't just be a relaxing break, but an upgrade for your mind too. 9 Space tourism could be big business – Jeff Bezos' Blue Origin has already shown off concepts for an Orbital Reef space station that could host holidaymakers Credit: Blur Origin 9 Travellers could pay large sums of money to enjoy off-Earth hols Credit: AFP EARTH, VIA SPACE Of course, space tourism isn't the only way rockets will help your holidays. Tim reckons it'll make moving around Earth easier too. Holidays to the Moon will involve blasting off from Earth and landing on the rocky satellite. But that's not the only version of going space – you can also take suborbital flights that skim space, and descend back to Earth. 9 'Some of those missions they're launching, say, from New Mexico. They're going up and landing in New Mexico,' Tim explained. 'Having been into space, well, there's no reason why you couldn't launch in New Mexico and land in Paris on that same kind of mission. 'And that could be a new form of suborbital transportation that becomes very popular in the future.' It sounds nightmarishly expensive – and it probably would be at the start. 9 Tim Peake was the Randox Future Lab Ambassador at this year's Goodwood Festival of Speed Credit: Nicole Hains / Goodwood Festival of Speed But eventually, Tim thinks, we could see the cost come down. Speaking to the astronaut, I joke that we could see Ryanair-style budget flights that only cost a tenner. 'I mean, if you if you went back to those early 1920s, 1930s transatlantic carriers, you would have found very wealthy people on board traveling in relative luxury,' Tim told me. 'And if you'd have said, you know, in 100 years time, we're going to have the EasyJets and the Ryanairs – a mass global transportation at the same cost of a train ticket – they would never have believed it. 'So you never know what we can do with future changes in technology.'
